Remove international
article thumbnail

Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

Bio Pharma Dive

Now, a push for an international floor could disrupt their R&D accounting. tax law changes enacted six years ago slashed large pharma companies' rates and saved them billions.

article thumbnail

Mastering Your Body’s Internal Clock Could Be The Key to Success

AuroBlog - Aurous Healthcare Clinical Trials blog

For early risers and late-nighters alike, listening to your internal clock may be the key to success. Circadian rhythms are powerful internal timekeepers that drive a person’s […] Timing is everything.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.

article thumbnail

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.

article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

article thumbnail

International Gaucher Alliance marks 30th year, unveils five-year strategic plan to 2029

Pharmaceutical Technology

In recognition of its 30th anniversary, the International Gaucher Alliance (IGA) unveiled a visionary five-year strategic plan extending to 2029.

130
130
article thumbnail

BI-1701963 by Boehringer Ingelheim International for Metastatic Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

BI-1701963 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Metastatic Colorectal Cancer.